Escala Medical

Market position

Escala describes the global POP treatment market as exceeding $7 billion, with more than 8 million women seeking care annually in the US and Europe, and states that nearly 50% of women over 40 experience POP while only about 10% undergo surgery. Competing approaches include suture passers and other anchor-based systems such as EnPlace, AnchorSure and Saffron; the company asserts these require incisions and an operating room, whereas Mendit is performed incision-free in an office setting.

The company positions Mendit as the first minimally invasive, incision-free and reversible anchor-based repair for pelvic organ prolapse, performed without cuts or mesh, under local anesthesia, and shifting the point of care from hospital operating rooms to physicians' offices with next-day return to normal activity.

Technology

Mendit is an anchor-based tissue approximation and fixation system that anchors sutures to pelvic floor ligaments through a transvaginal, incision-free route, suspending the vaginal apex from the sacrospinous ligament. The applicator is positioned by digital guidance, deploys an anchor within the ligament, and secures the repair with a button-type fixation element. The company describes the system as minimally invasive and reversible, and is developing a next generation of the device.

Go-to-market

In the United States, Escala launched commercially in October 2023 following FDA clearance and sells through its own direct sales force; the device has been approved for use in 48 hospitals, including several major health systems, with additional hospitals in advanced stages of approval. Mendit is approved by the Israeli Ministry of Health, CE mark approval is anticipated in 2026 to enable European market entry, and a distribution agreement with a Singapore-based partner covers Southeast Asia. Proceeds from the 2025 financing are allocated to US commercial expansion, European and Southeast Asian market entry, product enhancement and post-market clinical studies.

Hospitals, ambulatory surgery centers and private clinics, with procedures performed by gynecologists, urogynecologists and urologists. End patients are women with pelvic organ prolapse at early through late stages, including those who are ineligible for surgery, dissatisfied with supportive therapies such as pessaries, or unwilling to undergo invasive surgery.

Geography

Headquarters and R&D in Misgav Business Park, Israel (Escala Medical Ltd.), with a US entity, Escala Medical Inc., in Bethlehem, Pennsylvania. Commercial activity is concentrated in the United States, with regulatory approval in Israel, planned entry into Europe pending CE mark, and Southeast Asian distribution via a Singapore-based partner.

History

Founded in 2014 and incubated as a portfolio company of The Trendlines Group, Escala developed the Mendit anchoring system with Trendlines. The company received a €2.5 million EIC Accelerator grant in October 2023, obtained FDA clearance in April 2023 and launched commercially in the US in October 2023. In mid-2025 it completed a $4.5 million Series A round co-financed by the EIC Fund, bringing total funding above $8 million.

Risks & controversies

The company's European commercialization plans depend on CE mark approval, which had not yet been granted and was anticipated in 2026. Adoption depends on hospital-by-hospital approval processes, and the device competes with established surgical repair, pessaries and other anchor-based systems.